The Three Non-Negotiables of a Successful Digital Product in Regulated Industries

The desirability-viability-feasibility framework is not new. Anyone who has spent time in product development has seen the three-circle Venn diagram. But in my experience working with companies in insurance, healthcare, and financial services, I have watched this framework get applied as if every industry is a consumer app startup. It is not.

In regulated industries, the stakes behind each of these three dimensions are fundamentally different. Getting any one of them wrong does not just mean a failed feature. It can mean regulatory penalties, failed audits, lost licenses, or contractual breaches with enterprise clients.

Desirability Still Comes First, But the Buyer Is Not the User

In regulated industries, the person who wants the product and the person who buys the product are rarely the same. An insurance claims adjuster might desperately want a faster workflow tool. But the purchase decision runs through compliance, legal, IT security, and procurement before anyone signs a contract.

Desirability in this context means answering a harder set of questions:

Does this solve a problem that the end user feels daily? If the pain is not acute, adoption will stall regardless of what the contract says.
Does it solve a problem that the buyer will prioritize? Enterprise buyers in regulated industries have limited bandwidth for new vendor relationships. Your product needs to rank above the other fifteen things competing for their attention.
Can the buyer defend the purchase internally? In a regulated company, every software purchase gets scrutinized. Your product needs to make the buyer look smart, not create risk for them.

Validating desirability in this world requires more than landing page tests and user interviews. It requires conversations with compliance officers, procurement teams, and the executives who sign off on vendor risk assessments.

Viability Includes Regulatory Economics

For a consumer SaaS product, viability is mostly about unit economics: customer acquisition cost, lifetime value, churn rate. For a product in insurance, healthcare, or finance, viability includes an entire layer that most product teams underestimate.

Compliance costs are recurring. SOC 2 audits, HIPAA assessments, state insurance filings, PCI-DSS certifications. These are not one-time expenses. They are ongoing costs that must be factored into every pricing model.
Sales cycles are long. Enterprise buyers in regulated industries often take six to twelve months to close. Your capital plan needs to account for the runway required to survive those cycles.
Switching costs protect you, but they also trap you. High switching costs mean strong retention, but they also mean your product must deliver continuously. A regulated enterprise client that feels locked into an underperforming vendor becomes a detractor, not a reference.

Viability validation for scaling companies means modeling these dynamics before committing capital to a new product line or market entry. If you build first and model later, you discover your margins are thinner than expected after you have already spent the money.

Feasibility in Regulated Industries Is Not Just Technical

This is where the framework breaks down most often. In a typical product org, feasibility means: can we build it? Do we have the technical skills? Is the architecture sound?

In regulated industries, feasibility expands to include questions that many engineering teams are not equipped to answer:

Can we build it and maintain an audit trail? In healthcare and finance, every data mutation may need to be logged, traceable, and explainable. This is not a feature you bolt on later. It is an architectural decision that shapes the entire system.
Can we meet regulatory deadlines? If a state insurance commissioner requires a specific capability by a certain date, “we will get to it when we can” is not a feasible answer. Delivery has to be predictable enough to synchronize with external timelines.
Can we build it without introducing compliance risk? A feature that processes protected health information or financial data needs to be built with specific controls from day one. Retrofitting compliance into a shipped feature is expensive and risky.
Can we prove it works? In some regulated contexts, software needs to be validated, not just tested. The difference matters.

Feasibility in this environment is not a binary yes-or-no question. It is a question about whether you can deliver the right thing, in the right way, by the right time, with the right evidence.

Predictable Delivery Connects All Three

Here is what I have observed across dozens of engagements with scaling companies in regulated industries: the teams that struggle are not missing talent or ambition. They are missing the connective tissue between desirability, viability, and feasibility. That connective tissue is predictable delivery.

When delivery is predictable, you can validate all three dimensions before committing significant capital:

Desirability validation becomes time-boxed. You can tell your team: we have four weeks to validate demand with target buyers. Because you know your delivery capacity, you can scope the validation work and commit to a decision date.

Viability modeling becomes credible. When you know how long features take to deliver and how stable your throughput is, your financial models are built on real data instead of optimistic assumptions. Your CFO can trust the numbers because they are grounded in delivery reality.

Feasibility assessment includes delivery confidence. Instead of asking “can we build it?” you ask “can we deliver it by the regulatory deadline with 85% confidence?” That is a fundamentally different question, and it requires flow metrics — cycle time, throughput, WIP — to answer.

The Cost of Skipping Any One

I have seen a healthcare SaaS company build a product that users loved and the business model supported, but they could not pass a security audit because compliance was treated as a post-launch concern. Eighteen months of development, shelved.

I have seen an insurtech build a technically sound platform that met every compliance requirement, but nobody wanted to use it because they never validated desirability with actual adjusters and underwriters.

I have seen a fintech validate demand and build a compliant product, but the unit economics collapsed because they underestimated the cost of maintaining SOC 2 compliance and managing long enterprise sales cycles.

Each of these failures was preventable. Not with more effort, but with a system that forced validation of all three dimensions before capital was committed at scale.

What This Means for Your Next Product Decision

If you are leading a Series A through D company in a regulated industry, the three non-negotiables are the same as they are for any product. But the bar for each one is higher, the cost of failure is steeper, and the margin for error is narrower.

Before your next major product investment, ask:

Have we validated desirability with the actual buyers and the compliance stakeholders who influence the purchase?
Have we modeled viability including regulatory costs, long sales cycles, and ongoing compliance overhead?
Have we assessed feasibility not just as “can we build it” but “can we deliver it predictably, with audit trails, by external deadlines?”

If the answer to any of these is no, you are not ready to commit capital. And if you do not have a delivery system that gives you the data to answer these questions, that is the first problem to solve.